Revisiting RORγt Inhibition in Plaque Psoriasis: Lessons Learned from BI 730357

2025/05/27 by Hossein Akbarialiabad, Christopher G. Bunick · 1 voice
Immunology and Microbiology · Medicine · #Cytokine Signaling Pathways and Interactions #Neutrophil, Myeloperoxidase and Oxidative Mechanisms #Psoriasis: Treatment and Pathogenesis

paper · pdf · doi:10.1016/j.jid.2025.03.036

openalex publication_date 2025/05/27 · crossref created 2025/05/27 · crossref issued 2025/08/01 · crossref published 2025/08/01 · crossref published-print 2025/08/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29 · crossref deposited 2026/08/01 · crossref indexed 2026/08/01

Citations

• Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis

Discussions

• "Revisiting RORγt Inhibition in Plaque Psoriasis: Lessons learned from BI 730357," a commentary by Hossein Akbarialiabad & Christopher Bunick doi.org/10.1016/j.ji... #JIDJournal #DermatologyJournal #d [bsky, 0 points, 0 comments]